GlassScriptPhysician profile
Robert H Hale
NPI 1992704431
$4,679.45
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,527 · 2020: $824 · 2021: $1,043 · 2022: $770 · 2023: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $515.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,371.59 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $654.21 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $315.38 | 2019-2023 | Entyvio, Gattex |
| Janssen Biotech, INC. | $291.29 | 2019-2023 | Stelara, Remicade, Simponi Aria |
| Shionogi INC | $277.74 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $247.25 | 2019-2023 | Dificid, Zinplava |
| Pfizer INC. | $235.88 | 2019-2023 | |
| Gilead Sciences, INC. | $205.36 | 2019-2021 | |
| Braintree Laboratories, INC. | $128.55 | 2019-2022 | |
| Celgene Corporation | $128.05 | 2021-2023 | Zeposia |
| Daiichi Sankyo INC. | $126.14 | 2019-2023 | Injectafer |
| Ferring Pharmaceuticals INC. | $107.06 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $88.52 | 2020-2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $86.97 | 2019-2022 | |
| Ucb, INC. | $77.88 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $75.63 | 2021 | |
| Allergan, INC. | $51.23 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $39.91 | 2023 | Dupixent |
| Lexicon Pharmaceuticals, INC. | $22.86 | 2019 | |
| Vivus LLC | $19.14 | 2019 | |
| Organon LLC | $18.52 | 2023 | Renflexis |
| Redhill Biopharma INC. | $17.91 | 2020 | |
| Cook Medical LLC | $17.10 | 2021 | |
| Pharmacosmos Therapeutics INC. | $16.94 | 2022 | |
| Genzyme Corporation | $16.65 | 2022 | |
| Concordia Pharmaceuticals INC. | $14.07 | 2019 | |
| Qol Medical, LLC | $13.87 | 2023 | Sucraid |
| Olympus America INC. | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.